AU2022294022A1 - Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application - Google Patents

Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application Download PDF

Info

Publication number
AU2022294022A1
AU2022294022A1 AU2022294022A AU2022294022A AU2022294022A1 AU 2022294022 A1 AU2022294022 A1 AU 2022294022A1 AU 2022294022 A AU2022294022 A AU 2022294022A AU 2022294022 A AU2022294022 A AU 2022294022A AU 2022294022 A1 AU2022294022 A1 AU 2022294022A1
Authority
AU
Australia
Prior art keywords
group
methyl
pyrazol
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022294022A
Other languages
English (en)
Inventor
Patrick Bernardelli
Marc Bianciotto
Stéphanie Deprets
Laurent Dubois
John Macor
Frédéric PETIT
Corinne Terrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2022294022A1 publication Critical patent/AU2022294022A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AU2022294022A 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application Pending AU2022294022A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21315095.6 2021-06-15
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
EP22315117.6 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
AU2022294022A1 true AU2022294022A1 (en) 2024-02-01

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022294022A Pending AU2022294022A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Country Status (11)

Country Link
US (1) US20240383901A1 (https=)
EP (1) EP4355748A1 (https=)
JP (1) JP2024525150A (https=)
KR (1) KR20240021910A (https=)
AU (1) AU2022294022A1 (https=)
BR (1) BR112023025042A2 (https=)
CA (1) CA3223786A1 (https=)
CO (1) CO2024000083A2 (https=)
IL (1) IL309195A (https=)
MX (1) MX2023015016A (https=)
WO (1) WO2022263472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025141029A1 (en) * 2023-12-27 2025-07-03 Sanofi Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES

Also Published As

Publication number Publication date
KR20240021910A (ko) 2024-02-19
IL309195A (en) 2024-02-01
BR112023025042A2 (pt) 2024-02-27
MX2023015016A (es) 2024-05-31
CA3223786A1 (en) 2022-12-22
CO2024000083A2 (es) 2024-04-08
EP4355748A1 (en) 2024-04-24
JP2024525150A (ja) 2024-07-10
WO2022263472A1 (en) 2022-12-22
US20240383901A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
EP2678338B1 (en) Pyrazolo[1,5-a]pyridines as trk inhibitors
EP2569314B1 (en) Fused bicyclic kinase inhibitors
AU2019264640A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
JP2022523981A (ja) 抗癌剤として有用な縮合三環式化合物
JP2021532061A (ja) 四環式ヘテロアリール化合物
HUE028723T2 (en) Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
MX2011001333A (es) Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
JP2023523863A (ja) 新規大環状ｌｒｒｋ２キナーゼインヒビター
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
WO2012068450A1 (en) Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EA032081B1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN116057045A (zh) 成纤维细胞生长因子受体激酶抑制剂
WO2019031990A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
JP2022502440A (ja) モノアシルグリセロールリパーゼ調節因子
EP4355748A1 (en) Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application
JP2023518511A (ja) モノアシルグリセロールリパーゼ調節因子
JP2024512449A (ja) 大環状ｌｒｒｋ２キナーゼ阻害剤
CN111655690A (zh) 吡唑并吡啶酮化合物
US12570640B2 (en) 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
EP4105218A1 (en) Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
ES2771151T3 (es) Derivados de piperidina como inhibidor de señalización wnt
CN117881681A (zh) 经取代的吡咯并[2,3-d]嘧啶、其制备及其治疗应用
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
MD4313293T2 (ro) Derivati de tetrahidrotienopiridine ca inhibitori DDR